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KRAS is one of the most frequently mutated onco-
genes in human cancer. Despite substantial efforts,
no clinically applicable strategy has yet been devel-
oped to effectively treat KRAS-mutant tumors.
Here, we perform a cell-line-based screen and
identify strong synergistic interactions between
cell-cycle checkpoint-abrogating Chk1- and MK2 in-
hibitors, specifically inKRAS- andBRAF-driven cells.
Mechanistically, we show that KRAS-mutant cancer
displays intrinsic genotoxic stress, leading to tonic
Chk1- and MK2 activity. We demonstrate that simul-
taneous Chk1- and MK2 inhibition leads to mitotic
catastrophe in KRAS-mutant cells. This actionable
synergistic interaction is validated using xenograft
models, as well as distinct Kras- or Braf-driven
autochthonous murine cancer models. Lastly, we
show that combined checkpoint inhibition induces
apoptotic cell death inKRAS- orBRAF-mutant tumor
cells directly isolated from patients. These results
strongly recommend simultaneous Chk1- and MK2
inhibition as a therapeutic strategy for the treatment
of KRAS- or BRAF-driven cancers.146 Cell 162, 146–159, July 2, 2015 ª2015 Elsevier Inc.INTRODUCTION
In response to genotoxic stress, cells activate a complex,
kinase-based signaling network, which is commonly referred to
as the DNA damage response (DDR) (Jackson and Bartek,
2009). Cells progress through a series of cell-cycle checkpoints
prior to mitosis. These checkpoints allow time to repair DNA
lesions or, if damage is excessive, lead to the induction of
apoptosis (Jackson and Bartek, 2009). Thus, checkpoint
signaling can be seen as an effective fail-safe mechanism to pro-
vide and maintain genome stability through cell-cycle arrest with
subsequent DNA repair or apoptotic elimination of mutated,
incipient cancer cells.
The canonical DDR network consists of two major kinase
signaling branches, which operate through the upstream kinases
ATR and ATM, as well as their downstream effector kinases
Chk1 and Chk2, respectively (Jackson and Bartek, 2009). A third
checkpoint effector pathway, mediated through TAO- and p38-
dependent MK2 activity, was recently identified (Reinhardt and
Yaffe, 2013). The p38/MK2 pathway is a global stress-kinase
pathway that operates in parallel to Chk1. In response to DNA
damage, this pathway is recruited as part of the ATM/ATR-
dependent checkpoint signaling network (Reinhardt and Yaffe,
2013). Chk1 and MK2 control checkpoint initiation and mainte-
nance, respectively (Reinhardt et al., 2010). The activity of both
kinases converges on mediating inhibitory phosphorylations on
CDC25 family members to induce a subsequent cell-cycle arrest
by blocking CDC25B-dependent CDK activation (Reinhardt and
Yaffe, 2013).
We predicted that simultaneous Chk1- and MK2 inhibition
might result in synergistic effects through efficient checkpoint
abrogation. In spite of the clinical need for targeted combination
therapies, no generally accepted experimental and mathemat-
ical procedures for the reliable detection of synergistic drug in-
teractions have been implemented thus far. For this purpose,
we developed a software tool that was specifically engineered
to enable a reliable detection of synergistic drug interactions
and allows integration with genomic data. Using this tool, we
addressed the question of whether inhibition of Chk1 and MK2
results in synergistic cytotoxic effects. Surprisingly, we found
that KRAS-mutant cell lines display an actionable dependence
on functional checkpoint signaling. These observations were
validated in murine models and primary patient material.
RESULTS
Development of a Computational Tool to Identify
Synergistic Drug Interactions
The biological effect of a given compound is typically measured
by its GI50 value, which defines the concentration at which the
half-maximal biological effect is observed (Dietlein et al., 2014).
For this purpose, biological effects are usually determined at
various concentrations (Supplemental Experimental Proce-
dures, General Outline, Notation and Definitions, and Interpola-
tion of Compound Activity sections). Based on their single-agent
activities, the combined effect of two compounds can be classi-
fied as additive, synergistic, or antagonistic. To detect synergis-
tic interactions, an appropriate model for compound additivity
and a measure of synergistic deviation from this model are
required.
We developed a potency-adapted compound additivity model
(PACAM), which generalizes the concept of Loewe additivity
(Loewe, 1953) to non-linear dose-effect relationships (Supple-
mental Experimental Procedures, Additivity Models section).
PACAM generates a GI50 curve that runs through all concentra-
tion pairs for which single-agent activities add up to half-maximal
effect (Figure S1A). We compared the PACAM-derived GI50
curve with an experimentally observed GI50 curve and quantified
the area enclosed by these curves (synergy area) as a measure
for synergy. Depending on the relationship between expected
and observedGI50 curves, additive, synergistic, and antagonistic
drug interactions can be discriminated (Supplemental Experi-
mental Procedures, Synergism Quantification section).
To facilitate automated synergism calculations in high-
throughput screens, we developed the PreCISE (predictor of
chemical inhibitor synergistic effects) software (Data S1). Pre-
CISE derives synergism scores from two-dimensional matrices
consisting of cytotoxicity data achieved by combinations of
two compounds applied at individually varying concentrations.
In essence, a matrix consisting of m 3 n individual cytotoxicity
measurements is derived from m concentrations of compound
A combined with n concentrations of compound B (Figure 1A,
top left). For each cell line examined, PreCISE first generates
an expected GI50 curve derived from single-agent activity(Figure 1A, bottom left) based on our PACAM model (Figure 1A,
bottom middle; Supplemental Experimental Procedures, Addi-
tivity Models section). Next, PreCISE derives an observed GI50
curve from experimental data (Figure 1A, top middle, Supple-
mental Experimental Procedures, Interpolation of Compound
Activity section). The synergy area enclosed by the observed
and expected GI50 curves is then quantified by PreCISE (Fig-
ure 1A, top right, orange area; Supplemental Experimental
Procedures, Synergism Quantification section). This allows
discrimination between additive, synergistic, or antagonistic in-
teractions (Figure 1A, bottom right). Further, PreCISE inspects
the concentration matrix to determine the optimal dose combi-
nation at which maximal synergy is achieved (Figure 1A, bottom
right; Supplemental Experimental Procedures, SynergismQuan-
tification section). Finally, PreCISE derives a measure for the
quality of the screening data, which then allows the automated
identification of those cell lines for which screening data are
too noisy to allow a definite interpretation (Supplemental Exper-
imental Procedures, Synergism Quantification section).
We tested PreCISE against previously published approaches
for synergy calculation. Compared with synergism scores
derived by Bliss independence, we found that PreCISE dis-
played improved compensation of technical data noise (Fig-
ure S1B). Further, PreCISE was in strong concordance with the
Horizon Chalice Analyzer Software (Figure S1C), which quan-
tifies synergy based on an elevated Loewe model (Leha´r et al.,
2009). This confirmed the general validity of our approach.
A Cell-Line-Based Screen Identifies Oncogenic KRAS
as a Predictor for Synergistic Interactions between
Chk1- and MK2 Inhibitors
Single-agent checkpoint abrogators have largely failed to show
clinical efficacy (Curtin, 2012). We hypothesized that combined
checkpoint inhibition through the use of Chk1- and MK2 inhibi-
tors might overcome this limitation, as these kinases operate in
parallel pathways (Reinhardt et al., 2010). In order to identify syn-
ergistic interactions between Chk1- and MK2 inhibitors on a
panel of 96 cancer cell lines, we employed PreCISE to analyze
combinatorial cytotoxic effects of both compounds at six
varying concentrations (Figure 1B and Table S1). We used
PF477736 and PF3644022 as specific Chk1- andMK2 inhibitors,
respectively.
We observed strong synergistic effects between PF477736
and PF3644022 in 33 out of the 96 cell lines (referred to as
synergistic lines) (Figure 1B, Table S1, and Data S2). These
effects appeared to be specific to dual checkpoint abrogation,
as replacement of the Chk1 inhibitor PF477736 with the
PARP1 inhibitor AZD2281 did not display any synergy with the
MK2 inhibitor (Figure 1B).
We next aimed to identify recurrent genetic alterations that
dictate the synergistic effects between Chk1- and MK2 inhibi-
tors. To this end, we compared the mutation frequency
of 1,319 cancer-associated genes between synergistic and
non-synergistic cell lines (Supplemental Experimental Proce-
dures, Selection of Mutations and Significance of Mutations as
Synergy Predictors sections). As a further measure of predictive
strength, we calculated the ratio of synergy scores between
mutant and non-mutant cell lines (synergy ratio) (Figure 1C andCell 162, 146–159, July 2, 2015 ª2015 Elsevier Inc. 147
Figure 1. A Compound Interaction Screen Reveals a Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer
(A) Scheme of the PreCISE algorithm for the detection of synergistic interactions between compounds A (red) and B (green). Viability measurements in response
tom3 n concentration (conc.) pairs (top left) were used to derive single-agent activities (bottom left) and an observed cGI50 curve (brown, top middle). Based on
the activity of A and B, an expected cGI50 curve (orange) was inferred (bottommiddle). The synergy area (orange) enclosed by the observed and expected curves
(top right) served as a measure for synergy between A and B. PreCISE returns either additive or synergistic effects between compounds A and B (bottom right).
See Figures S1A–S1C for further technical details about PreCISE. See Data S1 for an executable version of the PreCISE software.
(legend continued on next page)
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Supplemental Experimental Procedures, Synergy Ratios sec-
tion). In brief, we separated the screening panel into mutant
and wild-type cells for each gene. We then determined the
average synergy for both of these sub-cohorts and then calcu-
lated the ratio between these values. We found that oncogenic
KRAS mutations emerged as the most significant (q = 5.68 3
107) mutational predictor for synergistic effects between
Chk1- and MK2 inhibitors (Figure 1C). Furthermore, KRAS dis-
played the highest synergy ratio of all the 1,319 genes (R =
3.89). Although substantially less significant, activating muta-
tions in BRAF (q = 1.19 3 103), which is a direct downstream
target of KRAS, emerged as an additional predictor of synergy
between Chk1- and MK2 inhibitors (Figure 1C).
We next validated the specificity ofKRAS andBRAFmutations
as predictors of synergism between Chk1- and MK2 inhibitors in
isogenic NIH3T3 cell lines that were transduced with an empty
vector, EGFRL858R, KRASG12V, or BRAFV600E (Figures S1D and
S1E). As shown in Figure S1D, combined inhibition of Chk1
and MK2 induced massive apoptosis specifically in KRASG12V-
and BRAFV600E-expressing cells, whereas neither compound
alone resulted in substantial apoptosis. We next assessed the
long-term effect of dual checkpoint inhibition using clonogenic
survival assays. These experiments revealed an almost com-
plete eradication of KRASG12V- and BRAFV600E-expressing cells,
whereas empty vector- or EGFRL858R-transduced cells were un-
affected following 72 hr of simultaneous Chk1/MK2 inhibition.
Single-agent Chk1 or MK2 inhibition had no substantial effect
in any of these assays (Figure S1E).
We next examined whether recurrent focal somatic copy
number alterations (SCNAs) might predict synergistic effects
between Chk1- and MK2 inhibitors. For this purpose, we
compared synergistic and non-synergistic cell lines at each
genomic locus, which displayed recurrent focal SCNAs (Supple-
mental Experimental Procedures, Copy Number Analysis
section). As shown in Figure 1D, focal and homozygous deletions(B) Synergy screening of 96 cell lines reveals a synergistic interaction between C
PF3644022 (MK2i) in combination with either AZD2281 (PARPi) or PF477736 (Ch
that were either exposed to DMSO (left), AZD2281 (2 mM), or PF477736 (0.5 mM).
hierarchical clustering of expression signatures (clustering tree). Mutation and SCN
between synergistic and non-synergistic cell lines (false-discovery rates, top). See
this screen.
(C and D) Volcano plot representation of a systematic association ofmutations (C)
MK2 inhibitors. For each gene, significance (false discovery rate, y axis) is plotte
mutant/non-deleted cell lines. Genes for whichmutation (C) or deletion (D) status a
red or blue, respectively. Circle sizes encode mutation (C) or deletion (D) freque
Figures S1D and S1E for a validation of the specificity of mutations and deletion
(E and F) The synergistic interaction between PF477736 and PF3644022 (validati
was examined across a panel of 25 cell lines and correlated (Pearson correlation,
lines depict least-squares regression. See Figures S2A and S2B for a genetic va
(G and H) Illustration of inhibitor binding by ribbon diagrams (turquoise, helix C; o
sphere, water molecule; yellow dots, hydrogen bonds). Anticipated binding mode
ATP binding cleft (PDB: 4FT5) based on either a pharmacophore model or the cr
PF3644022 ([G], bottom) into the MK2 ATP binding pocket was derived from the a
fit into the MK2 ATP binding cleft by adapting the conformation of a closely relat
(I) Identification of inhibitor concentration pairs, which result in maximal synergis
(HCC44, H1437, and HT29) and one non-synergistic control (H2172). Dose-respon
absence (turquoise) of a fixed concentration of PF3644022 (2 mM,MK2i) were com
presence of a fixed concentration (0.5 mM) of PF477736 (bottom). Blue arrows m
(J) MK2 inhibition sensitizes synergistic cells to Chk1 inhibition. The stacked bar
(purple, MK2i) and PF477736 (Chk1i) in the absence (turquoise) or presence (oraof CDKN2A were significantly enriched (q = 1.42 3 103) in the
cohort of synergistic cell lines and constituted the most signifi-
cant SCNA-based predictor for synergy between Chk1- and
MK2 inhibitors. Several genes located in close genomic prox-
imity to CDKN2A, such as PTPRD, also emerged as significant
predictors (Figure 1D). However, RNAi-mediated Cdkn2a
depletion in NIH 3T3 cells rendered these cells sensitive against
combined Chk1 and MK2 inhibition, both in apoptosis and
colony survival assays (Figures S1D and S1E).
Together, our data suggest that activating KRAS or BRAF
mutations and CDKN2A deletions are associated with non-
oncogene addiction to checkpoint signaling (Figures 1C, 1D,
S1D, and S1E), as evidenced by a synergistic drug interaction
between Chk1- and MK2 inhibitors (Figure 1B). Other potent
cancer-driving genomic aberrations, such as mutations in
EGFR, PIK3CA, and LRP1B, as well as amplifications of MYC
and ERBB2 or deletions of PTEN, although well-represented in
our cell line panel, did not significantly co-cluster with sensitivity
to dual checkpoint blockade (Figure 1B).
Pharmacological and Genetic Validation
of the Synergistic Interaction between
Chk1- and MK2 Inhibitors
To validate the reproducibility of our screening data, we
compiled a 25 cell line re-examination panel consisting of nine
KRAS-mutant lines (HCC44, H2030, H1792, H2347, H460,
H647, H2122, ASPC1, and Calu1), two BRAF-mutant lines
(RPMI7951 and HT29), four CDKN2A-deleted lines (H1437,
H1793, H2087, and KYSE510), and ten non-synergistic control
lines (H1341, H1703, H524, H2286, H596, H2172, H1975,
H1915, HCC15, and MDAMB436). We re-profiled this panel
using a matrix consisting of 10 3 12 concentration pairs (valida-
tion screen 1, Figure 1E). To exclude structure-specific off-target
effects, we re-screened the re-examination panel by replacing
PF477736 and PF3644022 with alternative Chk1- and MK2hk1- and MK2 inhibitors. Cells were treated with 6 3 6 concentration pairs of
k1i). Heatmaps encode synergistic effects induced by PF3644022 on cell lines
Cell lines were arranged into synergistic (red) and non-synergistic cell lines by
A status of 13 genes are annotated. Gene alteration frequencies are compared
Table S1 for annotation and screening results. See Data S2 for the raw data of
and deletions (D) in 1,319 geneswith synergistic interaction betweenChk1- and
d against the ratio of average synergism scores in mutant/deleted versus non-
re significantly associated with synergistic compound interaction are colored in
ncy. (D) Inset: genomic position of significant genes on chromosome 9. See
s.
on screen 1, [E]) as well as LY2603618 and SC221948 (validation screen 2, [F])
R) with the synergy scores obtained in the in the initial screen. Orange dashed
lidation of compound targets by RNAi.
range, hinge region; gray, DFG motif; blue sphere, peptide backbone NH; red
s of PF477736 ([G], top) and LY2603618 ([H], top) were modeled into the Chk1
ystal structure of a closely related homolog (PDB: 4FT5). The binding mode of
ppropriate complex crystal structure (PDB: 3FYJ). SC221948 ([H], bottom) was
ed analog (PDB: 2P3G).
tic effects. Concentration optimization is shown for three synergistic cell lines
se curves (logistic interpolation) of PF477736 (Chk1i) in the presence (brown) or
pared (top). Vice versa, activity of PF3644022 was compared in the absence or
ark inhibitor concentrations, which display maximal synergistic effects.
graph displays the half maximal inhibitory concentrations (GI50) of PF3644022
nge) of PF3644022 (2 mM, MK2i) across 25 cell lines.
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inhibitors that were based on entirely distinct chemical motifs
(Figure 1F). PF477736 was exchanged against the pyrazinyl-
urea LY2603618, and PF3644022 was replaced with the
pyrrolo-pyridinone SC221948 (validation screen 2, Figures 1G
and 1H). The synergy scores retrieved in both re-screening
experiments were highly correlated with the results from our
initial screen (R = 0.93, validation screen 1; R = 0.88, validation
screen 2, Figures 1E and 1F).
For target validation, we used RNAi to deplete Chk1 and/or
MK2 in three synergistic cell lines and two non-synergistic con-
trols (Figure S2A). Co-transduction with shRNAs targeting Chk1
and MK2 resulted in substantial cytotoxicity with less than 9%
survival in the synergistic cell lines, whereas the control lines
remained largely unaffected (Figure S2B). Isolated depletion of
Chk1 induced a mild reduction of cellular viability, whereas
knockdown of MK2 had no substantial effect (Figure S2B).
Thus, genetic repression of Chk1 and MK2 phenocopied the
effects observed when these kinases were pharmacologically
inhibited.
Finally, we aimed to determine the PF477736 and PF3644022
concentrations at which the strongest synergistic interaction
could be observed. To this end, we compared the efficacy of
each compound in the presence or absence of a stepwise fixed
concentration of the second inhibitor (Figure 1I). This analysis
revealed that a combination of 0.5 mM PF477736 and 2.0 mM
PF3644022 maximized the synergistic effects. Using these con-
centrations, the potency of PF477736 and PF3644022 as single
agents and in combination was quantified on the panel of 25 cell
lines that we had used in the validation screens (Figures 1E and
1F). As shown in Figure 1J, MK2 inhibition did not substantially
reduce cellular viability when PF3644022 was used at concen-
trations up to 7.5 mM. Although the Chk1 inhibitor PF477736
led to a moderate viability reduction in the majority of cell lines,
when used as a single agent, addition of 2.0 mM PF3644022
dramatically and selectively sensitized the panel of synergistic
cell lines to Chk1 inhibition (median 10.3-fold reduction in GI50
of PF477736, p = 8.1 3 104). In contrast, addition of the MK2
inhibitor to the non-synergistic lines did not result in any relevant
increase in Chk1 inhibitor toxicity (median 1.4-fold GI50 reduc-
tion). Thus, we applied PF477736 at 0.5 mM and PF3644022 at
2 mM in all subsequent experiments.
Dual Chk1/MK2 Inhibition Induces Apoptosis in
KRAS-Mutant Cancer Cells
To investigate whether combined Chk1/MK2 inhibition induces
apoptosis in synergistic cell lines, we assessed Annexin V/propi-
dium iodide (PI) double-positive cells in our re-examination panel
(Figures 2A, 2B, and S2C). Cells were exposed to PF477736
(0.5 mM), PF3644022 (2.0 mM), or a combination regimen for 0,
24, 48, and 72 hr. Combination treatment massively enhanced
the apoptosis observed in the synergistic cell lines, compared
to the effect of either compound alone. In contrast, addition of
the MK2 inhibitor to Chk1 inhibitor-treated non-synergistic cell
lines did not enhance the effects induced by PF477736 (Figures
2A, 2B, and S2C).
We next performed clonogenic survival assays. Cultures
were exposed to PF477736 (0.5 mM), PF3644022 (2.0 mM), or a
combination for 7 days. Inhibition of MK2 alone did not lead to150 Cell 162, 146–159, July 2, 2015 ª2015 Elsevier Inc.a substantial reduction in surviving colonies, whereas the Chk1
inhibitor induced a moderate reduction in clonogenic survival
in the synergistic cell lines. However, combined inhibition of
both Chk1 and MK2 almost completely eradicated the KRAS-,
BRAF-, or CDKN2A-altered cell lines, whereas non-synergistic
cell lines remained largely unaffected by the combination (Fig-
ures 2C, 2D, and S2D).
To further substantiate the synergistic effect of combined
Chk1/MK2 inhibition specifically in KRAS- or BRAF-mutant
cell lines, we next analyzed an additional panel of 18 KRAS-
and 6 BRAF-mutant human and murine cell lines that were not
included in the initial screening panel (Figures S3A and S3B).
Concordant with the data reported in Figures 1 and 2,
we observed a significant synergistic interaction between
Chk1- and MK2 inhibitors in KRAS- (Figures S3C and S3D, p =
4.94 3 105) and BRAF-mutant (Figures S3C and S3D, p = 1.15
3 103) cell lines. Of note, these mutations preserved signifi-
cance, even when the genetic analysis was restricted to the
sub-cohorts of pancreatic, lung, and colorectal adenocarci-
nomas (Figure S3E). In contrast, we found that single-agent ac-
tivity of the Chk1 inhibitor PF477736was restricted to a subset of
histotypes, including small-cell and squamous cell lung cancer,
aswell as hematopoeticmalignancies (Figure S3F).We conclude
that KRAS- and BRAFmutations are robust predictors of syner-
gistic interactions between Chk1- and MK2 inhibitors.
Dual Checkpoint Blockade Abolishes CDC25B
Phosphorylation in KRAS-Mutant Cells
To validate the activity of PF477736 and PF3644022, we as-
sessed their impact on the catalytic activity of Chk1 and MK2
by immunoblotting. Chk1 activity was gauged with an antibody
against the autophosphorylation site Ser-296, whereas pSer-
82 on HSP27 served as a marker for MK2 activity. Addition of
PF477736 led to a marked reduction of pSer-296 Chk1 in all
six cell lines examined (Figure 2E). Similarly, PF3644022 strongly
reduced pSer-82 HSP27 in all lines, except for H1703 cells, in
which no basal HSP27 phosphorylation was detectable. Etopo-
side treatment served as a positive control for Chk1 and MK2
activation (Figure 2E). These experiments demonstrate that
biochemical target inhibition is achieved with the doses of
PF477736 and PF3644022 used in this study.We note that base-
line pChk1 and pHSP27 appeared to be increased in synergistic
cells compared to non-synergistic cells (Figure 2E), suggesting
that both Chk1 and MK2 are tonically active in untreated syner-
gistic cell lines.
Given the basal activity of Chk1 and MK2 that we observed
in the synergistic lines, we speculated that this activity might
translate into enhanced basal CDC25B phosphorylation. Thus,
we assessed the levels of pSer-323 CDC25B in five synergistic
lines, four non-synergistic lines, and the Chk1 inhibitor-sensitive
H1703 cells. We observed a significant (p =0.005) baseline hy-
perphosphorylation of CDC25B in all five synergistic cell lines,
whereas none of the non-synergistic cell lines displayed any
substantial pCDC25B. H1703 cells displayed pCDC25B levels
similar to the synergistic lines (Figures S4A and S4B).
To corroborate the hypothesis that KRAS- or BRAF-induced
DNA damage leads to checkpoint activation and CDC25B inhibi-
tion, we employed an isogenic system. NIH3T3 cells were
Figure 2. Simultaneous Inhibition of Chk1 and MK2 Induces Genotoxic Stress and Apoptosis in KRAS-Driven Cancer Cells
(A) Inhibition of MK2 substantially increases the apoptotic effects induced by the Chk1 inhibitor PF477736 specifically in synergistic cell lines. A panel of 15
synergistic (red) and 10 non-synergistic (blue) cell lines was exposed to PF477736 (0.5 mM), PF3644022 (2 mM), or a combination (Chk1+MK2i) for 72 hr. The
stacked bar graph displays the induction of apoptosis, as assessed through flow-cytometry-basedmeasurement of the Annexin V/PI double-positive population.
(B) Measurement of apoptosis (24, 48, and 72 hr) under isolated or combined inhibition of Chk1 andMK2 is shown for three synergistic lines (HCC44, H1437, and
HT29) and one non-synergistic control (H2172). See Figure S2C for apoptosis measurements on the residual cell lines.
(C) Inhibition of MK2 increases the cytotoxic effects induced by the Chk1 inhibitor PF477736 specifically in synergistic cell lines. A panel of 25 cell lines was
exposed to PF477736 (0.5 mM,Chk1i) and PF3644022 (2 mM,MK2i) alone or in combination (Chk1i+MK2i) for 7 days. The stacked bar graph displays the induction
of cell death, which was determined as the relative difference between cell counts of compound- and vehicle-treated cultures.
(D) Clonogenic survival assays under isolated or combined 7 day inhibition of Chk1 (Chk1i) and MK2 (MK2i) are shown for three synergistic lines (HCC44, H1437,
and HT29) and one non-synergistic control (H2172). Scale bars, 500 mm. See Figure S2D for assays on eight additional lines. See Figure S3 for a validation of the
data shown in Figures 2A–2D on an independent cell line panel.
(E) Combined inhibition of Chk1 and MK2 abrogates CDC25B phosphorylation and induces genotoxic stress in synergistic cell lines. A panel of three synergistic
cell lines (HCC44, H1792, and H1437) two non-synergistic controls (HCC15 and H2172), and one Chk1 inhibitor-sensitive cell line (H1703) was exposed to
PF477736 (0.5 mM,Chk1i), PF3644022 (2 mM,MK2i), or a combination regimen for 12 hr. A 2 hr pulse of etoposide (25 mM) served as a positive control for induction
of DNA damage and checkpoint activation. pSer-296 Chk1, pSer-82 HSP27, and pSer-323 CDC25B were determined by immunoblotting. g-H2AX served as a
marker for genotoxic stress. Total protein levels of Chk1, HSP27, CDC25B, and HSP90 served as controls. See Figures S4A–S4F for basal phosphorylation of
CDC25B and H2AX.
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transduced with an empty vector, EGFRL858R, KRASG12V,
BRAFV600E, or a Cdkn2a short hairpin RNA (shRNA). We
observed a significant (p = 0.039) hyperphosphorylation of
CDC25B in KRASG12V-, BRAFV600E-, and Cdkn2a shRNA-ex-
pressing cells, compared to empty vector and EGFRL858R con-
trols (Figure S4C). We further found robust pCDC25B staining
in human pancreatic ductal adenocarcinoma specimens (n =
39), an entity in which more than 90% of cases carry oncogenic
KRAS mutations (Figure S4D) (Biankin et al., 2012). Lastly, we
observed strong pCDC25B staining in xenograft tumors derived
from H460 [KRASmut] and H1437 [CDKN2Adel] synergistic cell
lines, in contrast to tumors derived from non-synergistic cells
(Figure S4D).
To address the functional impact of combined Chk1- andMK2
inhibition on synergistic and non-synergistic cells, we next
exposed the cell line panel shown in Figure 2E to PF477736
(0.5 mM), PF3644022 (2.0 mM), or a combination regimen for
12 hr. Although neither Chk1- nor MK2 inhibition alone led to a
detectable repression of CDC25B phosphorylation, combination
treatment completely abolished pCDC25B in the synergistic
lines.
Coinciding with the complete removal of the inhibitory phos-
phorylation on CDC25B under combined Chk1/MK2 inhibition,
we observed a marked increase in genotoxic stress in these
cells, evidenced by strong g-H2AX positivity (Figure 2E). In
contrast, dual checkpoint inhibition did not result in the occur-
rence of detectable g-H2AX staining in non-synergistic cell lines,
whereas etoposide led to substantial genotoxic stress in these
cells, evidenced by g-H2AX staining and CDC25B phosphoryla-
tion (Figure 2E).
Our data prompted us to hypothesize that oncogene-driven
replicative stress in the synergistic cell lines might lead to the
constant induction of genotoxic damage, which is counteracted
by tonic activity of Chk1 and MK2. Concordant with this
hypothesis, we found that acute KRASG12D expression led to
the induction of genotoxic stress, evidenced by the occurrence
of g-H2AX foci and activation of Chk1 and MK2 in U2OS cells
and MEFs (Figures S4E and S4F). Our data support a model in
which oncogene-induced intrinsic hyperactivation of the check-
point machinery is the common denominator of synergistic cell
lines.
Checkpoint Abrogation Induces Mitotic Catastrophe
in KRAS-Mutant Cancer Cells
A hallmark of mitotic catastrophe is mitotic entry in the presence
of damaged DNA, resulting in the induction of apoptosis (Cas-
tedo et al., 2004). We showed that combined Chk1/MK2 inhibi-
tion prevented CDC25B phosphorylation, caused DNA damage,
and selectively induced apoptosis in synergistic cell lines. We
thus hypothesized that mitotic catastrophe might be the under-
lying mechanism leading to cell death of synergistic lines in
response to combined Chk1/MK2 inhibition. To substantiate
this hypothesis, we examined the distribution of genotoxic
lesions, caused by combined Chk1/MK2 inhibition, across
different cell cycle phases. We treated a panel of 6 synergistic
and 4 non-synergistic cell lines with PF477736 (0.5 mM),
PF3644022 (2.0 mM), or a combination for 0, 12, 24, or 48 hr
(Figures 3A–3C, S4G, and S4H).152 Cell 162, 146–159, July 2, 2015 ª2015 Elsevier Inc.Checkpoint abrogation in the synergistic lines HCC44 and
H1437 led to the accumulation of mitotic cells carrying DNA
lesions, as evidenced by the appearance of a substantial
g-H2AX/pHH3 double-positive population after 24 hr (Figures
3A and 3B). In contrast, the same treatment did not induce
g-H2AX-positive mitotic cells in non-synergistic H2172 cells
(Figure 3C). This difference in drug response between synergistic
and non-synergistic cell lines was statistically significant (p <
0.005 for S and M phase) when the entire panel of 10 cell lines
was analyzed (Figures S4G and S4H).
To prove that synergistic cell lines exposed to dual Chk1/MK2
blockade indeed undergomitotic catastrophe, we stained syner-
gistic and non-synergistic lines with antibodies against pHH3, g-
H2AX, and cleaved caspase-3 (CC3), a marker for apoptosis
(Figures 3D–3I and S4I–S4K). Triple-positive cells were scored
as undergoing mitotic catastrophe. Combination treatment
induced mitotic catastrophe in the synergistic cell lines, as
well as the Chk1 inhibitor-sensitive H1703 cells (Figures 3D–3I
and S4I–S4K). These cells appeared to be committed to death
specifically in mitosis, as no CC3 staining was observed in
g-H2AX-positive cells that did not also stain positive for pHH3
(Figures 3D and 3E, arrows versus arrowheads, Figures S4I–
S4K). In contrast, non-synergistic H2172 and H1975 cells dis-
played no signs of mitotic catastrophe, even when treated with
the combination therapy (Figures 3F, 3I, and S4I–S4K). Together,
our data suggest that the apoptosis, which we observed in syn-
ergistic cells, results from mitotic catastrophe.
Combined Chk1/MK2 Inhibition Is an Effective Regimen
for the Treatment of KRAS-Driven Xenograft Tumors
Wenext engraftedNMRInu/numice with 11 synergistic and 2 non-
synergistic control lines (Figures 4 and S5). Upon tumor forma-
tion, mice were treated with vehicle, PF477736 (15 mg/kg once
daily [q.d.]), PF3644022 (10 mg/kg q.d.), or a combination for
14 days. Inhibition of Chk1 or MK2 alone did not substantially
inhibit proliferation of the xenograft tumors (Figures 4A–4I and
S5A–S5D). In contrast, combined Chk1/MK2 inhibition led to a
significant reduction of the proliferation rates of tumors formed
by KRAS- (p = 3.59 3 109, n = 136, Figure 4J) or BRAF-mutant
(p = 1.583 107, n = 95, Figure 4K) cells, whereas control tumors
grew under dual checkpoint abrogation (Figures 4H and 4I). We
stained tumor sections forKi67 (FigureS5E) andCC3 (FigureS5F)
to gauge proliferation and apoptosis, respectively. Combined
Chk1/MK2 inhibition resulted in a substantial reduction of Ki67
staining (Figure S5E) and a robust increase in CC3 positivity (Fig-
ure S5F) in tumors formedbyKRAS-,BRAF-, orCDKN2A-altered
cell lines. The combination regimendid not lead to anydetectable
changes in Ki67- or CC3 staining in control tumors (Figures S5E
and S5F). No substantial changes in Ki67 and CC3 levels were
observed in any tumor treated with single-agent PF3644022 or
PF477736 (Figures S5E and S5F). These data suggest that the
checkpoint addiction of KRAS- and BRAF-mutant, as well as
CDKN2A-deleted cell lines, is preserved in vivo.
Autochthonous Kras- or Braf-Driven Tumors Display
Checkpoint Addiction
We next analyzed the mutation spectrum of 995 cancer cell lines
(Barretina et al., 2012). This analysis revealed that activating
Figure 3. Checkpoint Abrogation Induces Mitotic Catastrophe in Synergistic Cell Lines
(A–C) Simultaneous Chk1/MK2 inhibition allows mitotic entry of cells under genotoxic stress. KRAS-mutant HCC44 (A), CDKN2A-deleted H1437 (B), and non-
synergistic H2172 (C) cells were left untreated (control) or exposed to a combination of PF477736 (0.5 mM) and PF3644022 (2 mM) (Chk1i+MK2i) for 24 hr. Cells
were stained for pHH3 and g-H2AX and analyzed using flow cytometry. Cellular DNA content (PI staining) is plotted against g-H2AX- (top) and pHH3 signals
(bottom). Cells that were g-H2AX and pHH3 positive are shown as red squares. Cells that were exclusively positive for either g-H2AX or pHH3 are colored in blue
or yellow, respectively. Double-negative cells are shown in gray. See Figures S4G and S4H for a statistical analysis of these experiments.
(D–F) Combined Chk1/MK2 inhibition selectively induces apoptosis in mitotic cells. HCC44 (D), H1437 (E), and H2172 (F) cells were either left untreated (control)
or exposed to PF477736 (0.5 mM, Chk1i), PF3644022 (2 mM, MK2i), or a combination regimen (Chk1i+MK2i) for 24 hr. Cells were stained for g-H2AX, pHH3, and
CC3. Representative staining immunofluorescence (IF) images are shown. Arrowheads point to triple-positive cells, which undergo mitotic catastrophe. Arrows
mark DNA-damaged g-H2AX-positive cells, which are not in mitosis (pHH3 negative) and do not display signs of apoptotic cell death (CC3 negative).
(G–I) Quantification of the IF experiments shown in (D–F). Bar graphs display the average fraction of triple-positive cells (mitotic catastrophe, y axis) when left
untreated (control) or after exposure to PF477736 (0.5 mM,Chk1i), PF3644022 (2 mM,MK2i), or a combination regimen (Chk1i+MK2i) for 24 hr. For each condition,
250–500 independent cells were counted. Error bars display SDs. See Figures S4I–S4K for IF experiments on three additional cell lines.mutations in KRAS or BRAF (p = 0.0004), as well as CCND1 am-
plifications (p = 0.008), appear to be mutually exclusive lesions,
suggesting that a single alteration within the KRAS-BRAF-MEK-
ERK-Cyclin D1 pathway is sufficient for its tonic activation
(Figure S6A). Similarly, co-occurrence of alterations in TP53,
CDKN2A, and MDM2 was also significantly underrepresented
(p = 0.001 and p = 0.01, respectively) (Figure S6A). Furthermore,
cell lines carrying alterations in KRAS, BRAF, or CCND1 (KRAS
cluster) were significantly (p = 0.01) enriched for co-occurring
alterations in TP53, CDKN2A, or MDM2 (TP53 cluster) (Fig-
ure S6A). These data may suggest that cell lines carrying alter-
ations in the KRAS cluster might adapt to oncogenic stress by
simultaneous inactivation of the TP53 cluster.We next correlated genomic data with survival of lung adeno-
carcinoma patients (Cancer Genome Atlas Research Network,
2014) (Figure S6B). This analysis revealed that patients with
alterations in both theKRAS- and TP53 clusters displayed signif-
icantly (p = 6 3 104) reduced overall survival, compared to
patients with mutations in the KRAS- but not the TP53
cluster (Figure S6B). We next aimed to assess the efficacy of
dual-checkpoint inhibition in a mouse model that genetically
mimics these high-risk tumors carrying mutations in the KRAS-
and TP53 clusters. For this purpose, we employed an estab-
lished mouse model that allows conditional expression of
KrasG12D and simultaneous Tp53 deletion (DuPage et al., 2009)
(Figure 5A). Coherent with the clinical scenario (Figure S6B),Cell 162, 146–159, July 2, 2015 ª2015 Elsevier Inc. 153
Figure 4. Xenograft Tumors Derived from Synergistic Cell Lines Are Sensitive to Combined Chk1/MK2 Inhibition
(A–I) Simultaneous Chk1/MK2 inhibition inhibits growth of xenograft tumors formed by synergistic cell lines. Mice were engrafted with KRAS-mutant H460 (A),
639V (B), ASPC1 (C), and LS174 cells (D), as well as BRAF-mutant Colo205 (E), HT29 cells (F), and CDKN2A-deleted H1437 cells (G) and non-synergistic HCC15
(H) or H1975 (I) controls. Upon tumor formation, mice were treated with vehicle, PF3644022 (10 mg/kg, q.d., MK2i), PF477736 (15 mg/kg, q.d., Chk1i), or a
combination of both compounds (Chk1i+MK2i) for 14 days. Curves display average values of three independent experiments per group. Envelopes encode SD of
the combination treatment group (turquoise) or combined SD of control, Chk1-, andMK2 inhibitor-treated groups (orange). Significant differences are marked by
asterisks. See Figures S5A–S5D for four additional cell lines. See Figures S5E and S5F for an immunohistochemical analysis of these tumors after therapy
completion.
(J and K). Therapeutic response across 136 KRAS- (J) and 95 BRAF-mutant (K) xenograft tumors. Box-and-whiskers plots display relative tumor volumes (x axis)
of KRAS- (J) and BRAF-mutant (K) tumors after 14 day exposure to vehicle, Chk1 inhibitor, MK2 inhibitor, or a combination regimen. Boxes mark the interquartile
range, transverse lines represent themedian, and whiskers range fromminimal tomaximal value. Each circle represents the relative volume of an individual tumor
on day 14. Circle colors encode tumor histology. Groups were compared by two-tailed Student’s t test. Inset: pie chart representation of histotypes in the
xenograft tumor panel.KrasLSL-G12D/+;Tp53flox/flox (KP) animals display a significantly
(p = 4 3 103) worse survival compared to KrasLSL-G12D/+;
Tp53wt/wt animals (Figure S6C).154 Cell 162, 146–159, July 2, 2015 ª2015 Elsevier Inc.We next validated dual-checkpoint inhibition as a therapeutic
approach in KP mice. Upon tumor formation (Figure 5B), we
administered a 7 day course of PF477736 (15 mg/kg q.d.) and
Figure 5. Response of an Autochthonous Kras-Driven Lung Adenocarcinoma Model to Checkpoint-Abrogating Therapy
(A) Schematic representation of the mouse model. See Figures S6A–S6C for a detailed comparison of this mouse model with clinical data.
(B and C) mCT-based response assessment of tumor nodules. 5 weeks after AdCre application, lungs were imaged (mCT) to confirm tumor formation (baseline
image). After 7 days of vehicle (top) or checkpoint-abrogating therapy (bottom), mice were re-imaged. (B) mCT images before (left) and after completion of
treatment (right) are shown. Red arrows point to nodular target lesions used for response evaluation (RECIST 1.1). The heart is indicated (H). (C) Lesion volumes
were quantified after treatment and normalized to the pre-treatment values (x-fold change, y axis). Volume changes in the therapy cohort (red) were compared
with the vehicle-treated control group (blue) by two-tailed Student’s t test. Circle sizes encode the initial lesion volume. Significance level is indicated by asterisks.
(legend continued on next page)
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PF3644022 (10 mg/kg q.d.). Response was evaluated by micro
computed tomography (mCT). This analysis revealed significant
(p = 0.004) differences between the groups. Whereas vehicle-
treated tumors showed a volume gain within the 7 day observa-
tion period, lesion shrinkage was observed in most animals
treated with the combination therapy (Figures 5B and 5C). This
CT-morphological tumor response is reflected by an obvious
reduction in relative tumor content and a significant (p = 1.3 3
1015) reduction in Ki67-positive tumor cells in treated animals
(Figures 5D and 5E).
To address whether sensitivity to checkpoint abrogation
is preserved in individual tumor clones, we isolated cells
from 15 KP tumors. Combined Chk1/MK2 inhibition induced
apoptosis in all 15 clones, whereas isolated MK2- or Chk1 inhi-
bition failed to induce substantial levels of apoptosis in these
primary cells (Figure 5F). We note that 6 of the 15 lung cancer
cell lines were isolated from animals that succumbed to tumors
that relapsed after an initial cisplatin treatment (Figure 5F,
squares), suggesting that combined Chk1/MK2 inhibition might
be a therapeutic option for cisplatin-resistant lung cancer
patients.
Next, we asked whether combined Chk1/MK2 inhibition in-
creases the survival of KP animals. We administered three
5 day cycles of PF477736 (15 mg/kg q.d.) and PF3644022
(10 mg/kg q.d.) or vehicle control 5 weeks after AdCre inhalation.
As a control, we treated a separate cohort of animals with
cisplatin (7.5 mg/kg, 13 per week, for three cycles). Median sur-
vival of vehicle-treated animals was 115 days, and cisplatin
treatment failed to significantly (p = 0.956) enhance this survival
(117 days). In contrast, dual checkpoint abrogation significantly
prolonged median survival (150 days), compared with vehicle
(p = 0.027) and cisplatin (p = 0.007) controls (Figure S6D).
To ask whether checkpoint addiction was preserved in an
independent KRAS-driven entity, we employed a model of
high-grade sarcoma (Kirsch et al., 2007). Upon sarcoma forma-
tion, animals received a 7 day course of PF477736 (15 mg/kg
q.d.) and PF3644022 (10 mg/kg q.d.) or vehicle. Response
was monitored by MRI imaging and revealed a significant
(p = 2.38 3 105) difference in tumor volume change between
animals receiving vehicle or checkpoint abrogation (Figures 5G
and 5H). Whereas control animals showed significant tumor
progression (p = 0.0016), no significant volume change was(D) Checkpoint-abrogating therapy represses tumor cell proliferation. Chk1/MK2
Ki67 scores (right), indicating reduced proliferation. Turquoise arrows point to nod
which Ki67 proliferation scores are annotated (right). Scale bars, 3.5 mm (left), 5
(E) Quantification of Ki67 scores of individual nodular lesions treated with vehicle
tailed Student’s t test. Significance is indicated by asterisks.
(F) Cell lines (n = 15) were derived from individual tumors and exposed to PF36440
72 hr. Apoptosis was assessed by flow-cytometry-based measurement of the An
t test. Squares mark cell lines frommice that developed cisplatin resistance, wher
indicated by asterisks.
(G and H) MRI-based response evaluation of high-grade sarcomas. 30 days after
(baseline image). After completion of a 7 day treatment regimen with vehicle (top) o
early-stage (left) and late-stage (right) sarcomas before (left) and after therapy (rig
sarcoma expansion. (H) Sarcoma volume ratios before and after treatment (x-fol
tailed Student’s t test. Significance level is indicated by asterisks.
See Figure S6D for survival of the Kras-driven lung cancer model under combinat
driven colon cancer model to combined Chk1/MK2 inhibition.
156 Cell 162, 146–159, July 2, 2015 ª2015 Elsevier Inc.observed under treatment with combined Chk1/MK2 inhibition
(p = 0.193).
Finally, we assessed the effect of dual-checkpoint abroga-
tion in a Braf-driven mouse model. We employed Vil-Cre;
BrafLSL-V637E/+;p16Ink4a*/+ mice, which develop intestinal carci-
nomas through a hyperplasia/adenoma/carcinoma sequence
(Rad et al., 2013). At the age of 12 months, mice were treated
with a combination of PF477736 (15 mg/kg q.d.) and
PF3644022 (10 mg/kg q.d.) for 7 days. Tumor response was
assessed through IHC-based detection of CC3. This analysis
revealed a significant (p = 0.017) increase of CC3 positivity
scores compared with baseline staining intensities of untreated
tumors (Figures S6E and S6F). In particular, CC3 was detect-
able at medium or high levels in 92% (11/12) of all treated
tumors (scores 2, 3). In marked contrast, 93% (13/14) of the
control tumors were CC3 negative or displayed only low CC3
positivity (scores 1, 2) (Figures S6E and S6F). Thus, dual check-
point abrogation induced apoptosis in most Braf-driven individ-
ual intestinal lesions.
Clinical Extrapolation of Combined Chk1/MK2 Inhibition
in KRAS-Mutant Adenocarcinomas
To ask whether the intrinsic checkpoint activation that we
observed in KRAS-driven cancer cells is preserved in human
tumors, we compiled a cohort of 20 lung and 40 colon adenocar-
cinoma samples with known KRAS status. We performed
an IHC-based assessment of pChk2 and pMK2 levels, in order
to profile basal checkpoint activation. IHC intensity scores of
pChk2 were significantly higher in KRAS-mutant lung (p =
0.022) and colon carcinomas (p = 0.0034), compared with non-
mutant controls (Figures 6A and 6B). We further found that stain-
ing intensities of pMK2 paralleled the pChk2 intensity scores
(Figures 6A and 6B). These data suggest that KRAS-driven
tumors display intrinsically activated cell-cycle checkpoints,
rationalizing their Chk1/MK2 dependence.
We next assessed the effects of combined Chk1/MK2 inhibi-
tion in clinical specimens isolated from lung adenocarcinoma
patients. Cells were isolated from pleural effusions of 14 patients
who had received prior chemotherapy. Samples were character-
ized by high-coverage sequencing of 102 exons in 13 genes
(Figure S7A). Upon isolation, cells were immediately treated
with PF477736 (0.5 mM), PF3644022 (2.0 mM), or a combinationinhibition led to tumor volume reduction (middle) and a significant reduction in
ular tumor lesions (left middle). Red circles mark exemplary nodular lesions, for
00 mm (middle), and 100 mm (right).
control or combined Chk1/MK2 inhibition. Significance was calculated by two-
22 (2 mM,MK2i), PF477736 (0.5 mM, Chk1i), or a combination (Chk1i+MK2i) for
nexin V/PI double-positive population and compared by two-tailed Student’s
eas circles encode lesions from chemotherapy-naive mice. Significance level is
AdCre injection, hind legs were imaged using a small-animal solenoid MRI coil
r combined Chk1/MK2 inhibition (bottom), mice were re-imaged. (G) Images of
ht) are shown in a spectral fat suppression MRI sequence. Blue areas highlight
d change, y axis) are compared between vehicle and therapy cohorts by two-
ion therapy. See Figures S6E and S6F for response of an autochthonous Braf-
Figure 6. Clinical Extrapolation of a Synergistic Interaction between Chk1- and MK2 Inhibitors
(A and B) A cohort of 20 lung (A) and 40 colon (B) adenocarcinoma patient biopsies was stained for pChk2 and pMK2 to assess intrinsic checkpoints activation.
Median staining intensities of tumor cells were scored on a 4-tier scale. Exemplary images are shown for each staining intensity score together with genomic
annotation in KRAS, EGFR, and TP53, as well as microsatellite instability (MSI). Scale bars, 100 mm.
(C and D) Malignant cells from 13 pleural effusions were cultivated and either left untreated (green, baseline) or exposed to PF477736 (0.5 mM, Chk1i), PF3644022
(2 mM,MK2i), or a combination regimen (Chk1i+MK2i) for 48 hr. Apoptosis was quantified by flow cytometry. Inset: total apoptosis levels of each therapy regimen,
quantified as the area under the Annexin V histogram. (C) Apoptosis levels were compared between KRAS-mutant and non-mutant samples by two-tailed
Student’s t test. Significance values are denoted for each therapeutic intervention. (D) inset: pie chart representation of the KRAS mutation status in the lung
cancer patient cohort. See Figure S7A for a detailed genomic characterization of the patient cohort. See Figure S7B for a similar examination of cells isolated from
a BRAF-mutant patient. See Figures S7C and S7D for synergistic effects of Chk1- and MK2 inhibitors in primary pancreatic adenocarcinoma cells.for 48 hr (Figures 6C and 6D). Upon completion of drug expo-
sure, apoptosis measurements revealed that KRAS-mutant tu-
mor cells (n = 7) were significantly (p = 4.83 106) more sensitive
to the combination treatment than cells lacking KRAS or BRAF
mutations (n = 6) (Figures 6C and 6D). Furthermore, combined
Chk1/MK2 inhibition induced massive apoptosis in primary
tumor cells isolated from a pleural effusion of a patient withBRAFN581S-mutant (KRASwt) lung adenocarcinoma (Figure S7B).
Single-agent Chk1- and MK2 inhibitors did not have significant
apoptotic effects on patient-derived primary cells (p = 0.117
and p = 0.188, respectively) (Figures 6C, 6D, and S7B).
To validate these results, we employed KRAS-mutant pancre-
atic adenocarcinoma cells isolated from five independent human
tumor specimens (Vermeulen et al., 2008). Isolated Chk1 or MK2Cell 162, 146–159, July 2, 2015 ª2015 Elsevier Inc. 157
Figure 7. A Simplified Model for an Actionable Synergistic Inter-
action between Chk1- and MK2 Inhibitors in KRAS-Mutant
Adenocarcinomas
Oncogenic stress induced by KRAS mutations (KRAS cluster) leads to the
induction of DNA damage. Loss of functional p53 signaling either through
deletion ofCDKN2A, amplification ofMDM2, or TP53 alterations (TP53 cluster)
prevents DNA damage-induced apoptosis. In parallel, loss of functional p53
leads to destabilized cell-cycle regulation (e.g., through loss of p21 induction)
and thus induces checkpoint kinase dependence. Hence, simultaneous Chk1/
MK2 inhibition leads to a complete checkpoint collapse and subsequent
demise of KRAS-mutant cells in mitotic catastrophe.inhibition did not result in any cytotoxicity, whereas combined
checkpoint abrogation led to massive apoptosis (Figures S7C
and S7D, p = 7.16 3 107) in these cells. Thus, our data recom-
mend dual-checkpoint blockade as a therapeutic means to treat
KRAS-driven human malignancies.
DISCUSSION
Oncogenic Mutations in KRAS Are Associated with
Cell-Cycle Checkpoint Addiction
We showed that oncogenic KRASmutations are associated with
addiction to Chk1-/MK2-mediated checkpoints. We demon-
strated that acute expression of oncogenic KRAS induces
genotoxic damage. Intriguingly, we showed that KRAS-driven
cell lines are enriched for checkpoint-destabilizing cooperating
lesions, such as CDKN2A deletions or TP53 mutations. These
data indicate that malignant transformation of KRAS-driven
neoplastic lesions requires the concomitant inactivation of com-
ponents of the cell-cycle-regulating CDKN2A- or TP53 network
(Figure 7). Coherent with this hypothesis, early premalignant
lesions were recently shown to frequently display an accumula-
tion of DNA damage. This genotoxic damage in pre-malignant
lesions leads to the activation of the DDR network. As tumorigen-
esis progresses, incipient tumor cells appear to inactivate certain
components of the DDR (e.g., ATM, Chk2, and p53) to overcome
oncogene-induced senescence, suggesting that silencing DDR
signaling is a prerequisite for transformation (Bartkova et al.,
2006). This destabilization of the cell-cycle checkpoint machin-
ery, on the background of genotoxic stress-inducing KRAS
signaling, might rationalize the addiction of KRAS-driven tumor158 Cell 162, 146–159, July 2, 2015 ª2015 Elsevier Inc.cells to the remaining checkpoint kinases. Chk1 andMK2, which
have both been shown to be critical components of the G2/M
checkpoint, might be essential for preventing mitotic entry of
cells suffering from genotoxic damage (Reinhardt and Yaffe,
2013). In line with this hypothesis, we found CDC25B, a common
substrate of these kinases, to be constitutively phosphorylated
in KRAS-mutant carcinomas, suggesting that pCDC25B might
be a suitable biomarker to predict cell-cycle checkpoint
addiction. Furthermore, we could show that simultaneous inhibi-
tion of these checkpoint kinases in KRAS-driven cancer cells
leads to the accumulation of mitotic cells carrying genotoxic
lesions. We found that these damaged cells in M phase undergo
mitotic catastrophe, mechanistically rationalizing the synergistic
interaction observed between Chk1- and MK2 inhibitors.
Thus, our data now provide a strong rationale for the clinical
validation of combined checkpoint abrogation through the use




Cells were seeded into sterile 96-well plates and treated with various concen-
tration pairs of two different compounds for 96 hr. After completion of drug
exposure, we determined the relative ATP content in each well and normalized
it to a vehicle-treated control. We examined thesemeasurements for synergis-
tic effects between both compounds using the PreCISE software (Data S1).
Autochthonous Murine Cancer Models
We used LSL-KrasG12D/+;Tp53flox/flox (KP) mice as an autochthonous model
for KRAS-mutant adenocarcinomas. In order to generate Kras-driven lung
tumors, we applied a replication-deficient adenovirus expressing Cre to the
lungs of 8-week-old KP mice in anesthesia. 5 weeks after virus inhalation,
lungs were imaged by mCT imaging in order to confirm tumor formation. In
order to induce Kras-driven high-grade soft tissue sarcomas, we applied Cre
adenovirus to the hind legs of 6-week-old KP mice by intramuscular injection.
30 days after injection, hind legs were scanned by MR imaging in order to
confirm sarcoma formation. We used Vil-Cre; BrafLSL-V637E/+;p16Ink4a*/+ as an
autochthonous model for BRAF-mutant colon cancer. These mice develop
Braf-driven colorectal carcinomas at the age of 12 months. After tumor forma-
tion, animals were treated either with vehicle solution or with a combination
therapy of PF3644022 (10 mg/kg) and PF477736 (15 mg/kg) by daily intraper-
itoneal injections. After completion of the combination therapy, we examined
the tumor response either by mCT- or MR-based re-imaging or by staining
tumors for cleaved caspase-3.
Further details about the mathematical analysis, cell culture methods
and viability screening, crystal structure analysis, flow cytometry, clonogenic
survival assays, retro- and lentivirus production, immunoblotting, immunoflu-
orescence, murine cancer models, mCT and MRI imaging, immunohistochem-
istry, passaging, cultivation, and parallel sequencing of patient material are
described in the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, one table, and two data files and can be found with this article
online at http://dx.doi.org/10.1016/j.cell.2015.05.053.
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